Glaucoma drug Vyzulta, psoriasis remedy Skilarence win insurance benefit

28 January 2022 - The government granted health insurance benefits for Bausch Health Korea’s glaucoma treatment Vyzulta (latanoprostene bunod) and ...

Read more →

Highlights from CHMP 24-27 January meeting

28 January 2022 - EMA’s CHMP recommended seven medicines for approval at its January 2022 meeting. ...

Read more →

Recommendations made by the PBAC – December 2021 intracycle meeting

28 January 2022 - Recommendations made by the PBAC in December 2021 relating to the listing of drugs on the PBS ...

Read more →

The certainty of uncertainty in health technology assessment

26 January 2022 - History is replete with stories of poor decisions—catastrophes that leaders might have averted, and great opportunities that ...

Read more →

The price of cystic fibrosis drugs is still too high

27 January 2022 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has decided that Kaftrio and Kalydeco for cystic fibrosis ...

Read more →

ICER releases draft evidence report on novel agents to prevent chemotherapy-induced neutropenia

25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...

Read more →

Method paper: new version 6.1 comes into force

24 January 2022 - The innovations concern, among other things, the procedure for evidence searches for medical guidelines. New concept ...

Read more →

EMA publishes agenda for 24-27 Jan CHMP meeting

23 January 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

The G-BA classifies three drugs as reserve antibiotics

20 January 2022 - The Federal Joint Committee (G-BA) today exempted three drugs classified as reserve antibiotics from the regular early ...

Read more →

Immunotherapy with blinatumomab improves the chances of survival in very rare childhood blood cancer

20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant ...

Read more →

NICE moves: increased accessibility and flexibility for health tech

19 January 2022 - NICE also aims to make strides in digital, genomic and antimicrobial technologies ...

Read more →

NICE signals commitment to greater flexibility in its evaluation of promising new health technologies and making patient access fairer

20 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE for use in the ...

Read more →

UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile

19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...

Read more →

Early benefit assessment for new drugs 2021: G-BA sets a record with 146 completed procedures

10 January 2022 - At the beginning of the year, the Federal Joint Committee (G-BA) took stock of its assessment of ...

Read more →

Hyposensitisation with AR101 in peanut allergy: proof of lesser benefit

17 January 2022 - In the patient-relevant outcomes, there are only disadvantages for 4- to 17-year-olds compared to a pure peanut-avoiding ...

Read more →